Back to mobile site

Janney Defends Marker Therapeutics (MRKR), Says Buy on Weakness

July 21, 2019 4:35 PM EDT Send to a Friend
Janney analyst Yun Zhong reiterated a Buy rating on Marker Therapeutics (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login